Teaching Strengths
Dr Laura Eadie
School of Medicine
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Eadie is an award-winning biomedical researcher and a Cancer Council South Australia Beat Cancer Project Fellow, awarded to the top two mid-career cancer researchers in South Australia (2023-26). She is an Australian Institute of Policy and Science Young Tall Poppy (2023), previous Fulbright scholar and a TEDx speaker.Dr Eadie has been awarded >$4.4 million in fellowship/grant funding in the last five years, >$2.2 million as CIA from funding bodies including NHMRC, MRFF, Channel 7 Children's Research Foundation. Dr Eadie has built an international reputation as an emerging leader in the use of patient genomics to inform therapy outcomes for Acute Lymphoblastic Leukaemia (ALL) patients, evidenced by an American Society of Hematology Achievement Award (2020) and an International Thermo Fisher Cancer Research Grant (2022).ALL is one of the biggest causes of non-traumatic death in children and relapsed T-cell ALL (T-ALL) is a rare but high risk disease. More effective, less toxic treatments are urgently needed for when a patient fails their front-line chemotherapy. Innovative therapies for use in frontline treatment are also required. Dr Eadie is SAHMRI's T-ALL research leader and her team creates humanised mouse avatars from individual patient’s leukaemic cells to use in pre-clinical drug trials. Combined with genomic sequencing to identify a patient’s leukaemia-causing mutations, these models allow Dr Eadie to discover more effective therapeutic options targeted to each individual patient’s leukaemia.Dr Eadie's long-term research goal is to identify new and re-purposed drugs which effectively treat the different genomic lesions associated with T-ALL. Her team's findings will ultimately provide clinicians with an arsenal of alternative treatment options and hope for patients who have relapsed.
Acute Lymphoblastic Leukaemia (ALL) is one of the biggest causes of non-traumatic death in children and relapsed T-cell ALL (T-ALL) is an extremely high risk disease. Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. More effective, less toxic treatments are urgently needed for when a patient fails their front-line chemotherapy. Dr Eadie is SAHMRI's T-ALL research leader and her team creates humanised mouse avatars from individual patient’s leukaemic cells to use in pre-clinical drug trials. Combined with genomic sequencing to identify a patient’s leukaemia-causing mutations, these models allow Dr Eadie to discover more effective therapeutic options targeted to each individual patient’s leukaemia.
T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge.
Dr Eadie's long-term research goal is to identify new and re-purposed drugs which effectively treat the different genetic lesions associated with T-ALL. Her team's findings will ultimately provide clinicians with an arsenal of alternative treatment options and hope for patients who have relapsed.
Research Projects - Dr Laura Eadie
Title: Evaluation of novel alterations in pre-clinical models of T-cell Acute Lymphoblastic Leukaemia (T-ALL)
Project description:
Dr Eadie's research program utilises genomic sequencing to identify novel and targetable T-ALL alterations to accelerate a transition towards precision medicine to improve clinical outcomes. Dr Eadie's Research Group is part of the SAHMRI ALL Genomics and Functional Genomics/Biology Laboratory led by Prof Deborah White (leader, SAHMRI Precision Cancer Medicine Theme). Together, with the ALL bioinformatic team, Dr Eadie has curated the largest genomic sequencing database of T-ALL patients in Australia. Dr Eadie has identified novel leukaemia-causing alterations as well as new treatment options for several high-risk ALL subtypes.
SAHMRI's ALL Research laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients from Australia and New Zealand. Identification of novel and recurrent genomic alterations is ongoing and we have projects available to characterise these alterations in vitro and in vivo.
The over-arching focus of Dr Eadie's research program is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models are used to (1) examine re-purposed drugs and test novel therapies; (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease; (3) characterise the underlying biology of genomic subtypes of T-ALL.
Projects available for: HDR: Mphil / PhD
Location: SAHMRI
Research project start: Semester 1 or 2
Special requirements: Police Clearance
| Date | Position | Institution name |
|---|---|---|
| 2023 - ongoing | Cancer Council Beat Cancer Project Mid-career Research Fellow | SAHMRI |
| 2023 - ongoing | Lecturer, BIOCHEMISTRY III: Cancer, Stem Cells & Development | University of Adelaide |
| 2020 - ongoing | Affiliate Senior Lecturer | University of Adelaide |
| 2019 - 2023 | Peter Nelson Post-doctoral Research Fellow | SAHMRI |
| 2016 - 2017 | Post-doctoral Research Associate | St. Jude Children's Research Hospital |
| 2014 - 2020 | Affiliate Lecturer | University of Adelaide |
| 2013 - 2019 | Post-doctoral Researcher | SAHMRI |
| 2013 - 2013 | Post-doctoral Researcher | SA Pathology |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2024 | Award | SAHMRI High Impact Publication Award 2024 | SAHMRI | Australia | - |
| 2024 | Award | Len Frankham Award for the top-ranked application to the Channel 7 CRF Grants Program | Channel 7 Children's Research Foundation | Australia | - |
| 2024 | Award | Woman of the Year Award, Innovator Category Finalist | The Advertiser / Sunday Mail | Australia | - |
| 2023 | Award | Adelaide Medical School ‘Best inaugural senior author publication 2023’ | University of Adelaide | Australia | - |
| 2023 | Award | Young Tall Poppy Award | Australian Institute of Policy and Science | Australia | - |
| 2023 | Award | CASS Foundation Travel Grant | The CASS Foundation | Australia | $4000 |
| 2023 | Award | InDaily 40 under 40 Award for Innovation and Entrepreneurship | In Daily / Solstice Media | Australia | - |
| 2020 | Award | American Society of Hematology (ASH) Abstract Achievement Award | American Society of Hematology | United States | - |
| 2020 | Award | CASS Foundation Travel Grant | The CASS Foundation | Australia | $3500 |
| 2019 | Award | The HRF Research Travel Award | The Hospital Research Foundation | Australia | $4000 |
| 2018 | Invitation | Invited Speaker: Early/Mid-Career Researcher Seminar Series | The University of Adelaide | Australia | - |
| 2016 | Invitation | Judge: European Molecular Biology Laboratory (EMBL) Australian Postgraduate Symposium (EAPS) | - | - | - |
| 2016 | Invitation | Invited Speaker: 18th Annual ESH-iCMLF International Conference on CML – Biology and Therapy | - | - | - |
| 2016 | Invitation | Invited Speaker: 18th Annual ESH-iCMLF International Conference on CML – Biology and Therapy | - | - | - |
| 2016 | Invitation | Invited Speaker: International Conference on Cancer Immunology and Immunotherapy | - | - | - |
| 2013 | Award | Dean’s Commendation for Doctoral Thesis Excellence | - | - | - |
| 2011 | Award | HSANZ Non-Member Travel Grant | Haematology Society of Australia and New Zealand | Australia | $1000 |
| 2010 | Award | HSANZ Non-Member Travel Grant | Haematology Society of Australia and New Zealand | Australia | $1500 |
| 2010 | Award | New Scientist Award for Science and Technology in Society | Golden Key Honour Society | Australia | $1000 |
| 2009 | Scholarship | LFA PhD Scholarship | Leukaemia Foundation Australia | Australia | $157,500 |
| 2009 | Scholarship | Dawes Top-up Scholarship | Royal Adelaide Hospital Research Committee | Australia | $17,500 |
| 2009 | Scholarship | Baillieu Supplementary Research Scholarship | University of Adelaide | Australia | $30,000 |
| 2009 | Scholarship | NHMRC Biomedical Postgraduate Scholarship (unable to accept) | National Health and Medical Research Council | Australia | $65,598 |
| 2009 | Scholarship | Australian Postgraduate Award (unable to accept) | Australian Federal Government | Australia | $61,281 |
| 2008 | Award | HSANZ Non-Member Travel Grant | Haematology Society of Australia and New Zealand | Australia | $1000 |
| 2006 | Award | Australasian Society for HIV Medicine Junior Researcher Award | - | - | - |
| 2006 | Scholarship | Honours Scholarship | Royal Adelaide Hospital Research Committee | Australia | $5000 |
| 2005 | Scholarship | Summer Research Scholarship | Molecular Plant Breeding Cooperative Research Centre | Australia | $1500 |
| 2004 | Honour | Admittance to the Golden Key International Honour Society | - | - | - |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2009 - 2013 | University of Adelaide | Australia | PhD in Medicine |
| 2006 - 2006 | University of Adelaide | Australia | Honours Degree of Bachelor of Science |
| 2003 - 2005 | University of Adelaide, Adelaide | Australia | Bachelor of Science |
| Date | Title | Institution | Country |
|---|---|---|---|
| 2016 - 2017 | Fulbright Post-doctoral Research Scholarship | St. Jude Children's Research Hospital | United States |
| Year | Citation |
|---|---|
| 2020 | Tavakoli, P. S., Eadie, L., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib (Vol. 4). Lippincott, Williams & Wilkins. DOI |
| Year | Citation |
|---|---|
| 2024 | Eadie, L. (2024). Sudden refractory increase in end-tidal carbon dioxide: a diagnostic dilemma. In ANAESTHESIA Vol. 79 (pp. 69). ENGLAND, London: WILEY. |
| 2024 | Eadie, L. (2024). Gender disparity in lung ventilation volumes in intensive care. In ANAESTHESIA Vol. 79 (pp. 18). ENGLAND, London: WILEY. |
| 2023 | White, D. L., Rehn, J. A., Schutz, C. E., Heatley, S. L., Eadie, L. N., Thomson, A., . . . Greenwood, M. (2023). Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI |
| 2023 | Eadie, L. N., Schutz, C. E., Page, E. C., Conlin, T. S., Heatley, S. L., Lagonik, E., . . . White, D. L. (2023). Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2018 | Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins. DOI |
| 2015 | Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2013 | White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology. DOI |
| 2013 | Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology. DOI |
| 2010 | Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2010 | Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology. DOI |
| 2008 | White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY. WoS3 |
| 2008 | White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology. DOI |
| 2007 | Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS7 |
| 2007 | Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology. DOI |
| 2005 | Keiper, F., Scott, L., Eadie, L., Hayden, M., & Wallwork, H. (2005). Microsatellite (SSR) diversity among Australian Rhynchosporium secalis isolates. In 12th Australian Barley Technical Symposium Conference Proceedings, 11-14 September 2005 [CD-ROM] (pp. 6 pages). Hobart: Australian Barley Association. |
| Year | Citation |
|---|---|
| 2024 | Rehn, J., Heatley, S., Page, E., Eadie, L., Schutz, C., Thomson, A., . . . White, D. (2024). Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis. Poster session presented at the meeting of Blood Annual Scientific Meeting. |
| 2024 | Rehn, J., Page, E., Heatley, S., Eadie, L., Schutz, C., Thomson, A., . . . White, D. (2024). Genomic characterisation of PAX5alt B-cell acute lymphoblastic leukaemia reveals novel PAX5 fusions. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting. |
| 2023 | Rehn, J., Schutz, C., Page, E., Heatley, S., Eadie, L., McClure, B., . . . White, D. (2023). High expression of DUX4 mRNA is a reliable indicator of DUX4-rearranged acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology group (ANZCHOG) Scientific Meeting. |
| 2022 | Thomson, A., Rehn, J., Heatley, S., Eadie, L., McClure, B., Page, E., . . . White, D. (2022). Benchmarking the detection rate of IGH gene fusions in B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) Conference. |
| 2021 | Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2021). Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2021 | Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy. |
| 2021 | Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). |
| 2020 | Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting). |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting). |
| 2020 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia. |
| 2020 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT. |
| 2020 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT. |
| 2020 | Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2020 | Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference). |
| 2020 | Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference). |
| 2020 | Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2020 | Tavakoli, P., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent Activation of JAK/STAT Signaling Plays an Important Role in<i>in Vitro</i>Jaki Resistance in <i>TYK2</i>-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER. DOI |
| 2019 | Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology. DOI |
| 2019 | Tavakoli, P. S., Eadie, L., Heatley, S. L., & White, D. L. (2019). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting 2019. Christchurch, New Zealand. |
| 2019 | Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany. |
| 2019 | Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. |
| 2018 | Eadie, L. N., Mullighan, C., & White, D. L. (2018). Mutations to the transcription factor MYB alter cellular localization and decrease degradation likely enhancing oncogenicity in patients with T-cell ALL. Poster session presented at the meeting of NDLR. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of ASMR. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of SAHMRI Scientific Seminar. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of 12th Annual Florey postgraduate Conference. |
| 2018 | Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. |
| 2016 | Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA. |
| 2016 | Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA. |
| 2016 | Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY. DOI |
| 2016 | Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD. |
| 2016 | Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA. |
| 2016 | Leow, B., Eadie, L. N., Leclercq, T., & White, D. L. (2016). Drug resistance in CML: heterogeneity, selection, and clonal architecture. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2013 | White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2013 | White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. |
| Year | Citation |
|---|---|
| 2025 | Eadie, L. N., McDougal, D. P., Lagonik, E., Schutz, C. E., Conlin, T. S., Page, E. C., . . . White, D. L. (2025). The 5’ fusion partner modulates response to the STAMP inhibitor asciminib in <i>ABL</i> -rearranged ALL. DOI |
Dr Eadie has attracted >$4M in competitive funding, both as lead applicant and collaborator, including grants awarded by the MRFF and NHMRC. Below is a snapshot of key grants Dr Eadie has been awarded in the past 5 years.
2025. Investigating the role of the X gene in T-cell Acute Lymphoblastic Leukaemia development, $100k Channel 7 Children's Research Foundation.
2024. Molecular determinants and clinical outcomes of Australian Indigenous blood cancer: The first comprehensive survey, $884k MRFF – Early to Mid-Career Researchers Initiative.
2023. Modelling co-occurring mutations in T-ALL to enhance treatment options and maximise the power of next generation sequencing, $600k Cancer Council SA Beat Cancer Project Mid-Career Fellowship
2022. Modelling co-occurring mutations in T-ALL to enhance treatment options and maximise the power of next generation sequencing, in kind funding of ~$25k International Thermo Fisher Scientific Cancer Research Grant.
2021. Adolescents with Acute Lymphoblastic Leukaemia: Focussing on the gut microbiota, its role in therapeutic response and potential as an effective adjunct therapeutic in this High-Risk group, $1.3M MRFF – Emerging Priorities and Consumer Driven Research Initiative.
2019. Preclinical modelling of T-cell Acute Lymphoblastic Leukaemia – defining targeted therapies and preventing treatment resistance, $600k Peter Nelson Leukaemia Research Fellowship.
2019. Preclinical modelling of T-cell Acute Lymphoblastic Leukaemia – defining targeted therapies and preventing treatment resistance, $600k Cancer Council SA Beat Cancer Project Mid-Career Fellowship (awarded but unable to accept due to competing fellowship offers)
Undergraduate Teaching
Throughout her postgraduate training and postdoctoral research, Dr Eadie has been actively involved in the teaching, supervision and mentoring of undergraduate and honours students. In 2023 she was recruited as a third year lecturer to deliver the Molecular Biology of Cancer module within the Biochemistry course Cancer, Stem Cells and Development III. To date, Laura has been involved in the following University of Adelaide Faculty of Health and Medical Sciences courses as a project supervisor: Principle and Practice of Research III; Research Practice for Applied Biology III; Principles & Practice of Research (Advanced) I. She has also supervised two visiting international scholars from France undertaking 6 month research placements in her laboratory.
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2023 | Principal Supervisor | Modelling co-occurring mutations in T-cell Acute Lymphoblastic Leukaemia to enhance treatment options and maximise the power of next generation sequencing | Doctor of Philosophy | Doctorate | Full Time | Mr Maxim Jon Buckley |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2019 - 2022 | Co-Supervisor | Characterising KMT2A and MLLT10 Rearranged Acute Lymphoblastic Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Michelle Olivia Forgione |
| 2017 - 2021 | Co-Supervisor | Characterising the novel MYB-TYK2 fusion gene in high-risk acute lymphoblastic leukaemia: oncogenic potential, effective therapeutic strategies and In vitro modelling of drug resistance mechanisms | Doctor of Philosophy | Doctorate | Full Time | Miss Paniz Tavakoli Shirazi |
| 2015 - 2019 | Co-Supervisor | Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Mr Benjamin Chia Sing Leow |
| Date | Role | Research Topic | Location | Program | Supervision Type | Student Load | Student Name |
|---|---|---|---|---|---|---|---|
| 2025 - ongoing | Principal Supervisor | Investigating the transformative potential of the novel PHF6::IQSEC2 fusion gene in the development of T-cell acute lymphoblastic leukaemia | South Australian Health & Medical Research Institute | - | Honours | Full Time | Asma El-Kaissi |
| 2023 - 2023 | Principal Supervisor | Investigating asciminib sensitivity in NUP214::ABL1 T-cell Acute Lymphoblastic Leukaemia | South Australian Health & Medical Research Institute | - | Honours | Full Time | Tace Sian Conlin |
| 2020 - 2020 | Principal Supervisor | Investigation of oncogenic fusion genes in leukaemia and evaluation of the efficacy of ABL001 | South Australian Health & Medical Research Institute | - | Honours | Full Time | Elias Lagonik |
| 2018 - 2018 | Principal Supervisor | Investigating the efficacy of novel and combination therapies in Ph-like ALL | South Australian Health & Medical Research Institute | - | Honours | Full Time | Caitlin Schutz |
| 2014 - 2014 | Co-Supervisor | The effect of the T315I mutation on treatment failure in Chronic Myeloid Leukemia: a mere case of drug binding efficiency? | South Australian Health & Medical Research Institute | - | Honours | Full Time | Benjamin Leow |
| Date | Topic | Location | Name |
|---|---|---|---|
| 2020 - 2020 | Careers Mentoring | University of Adelaide | Hannah Bonham |
| 2020 - 2020 | Careers Mentoring | University of Adelaide | Mogana Reckdharajkumar |
| Date | Role | Committee | Institution | Country |
|---|---|---|---|---|
| 2025 - 2027 | Member | NDLR Scientific Organising Committee | New Directions in Leukaemia Research (NDLR) Conference 2026 | Australia |
| 2020 - 2021 | Representative | Australian Society for Medical Research SA Committee (Social Media Lead) | Australian Society for Medical Research | Australia |
| 2019 - 2019 | Treasurer | Australian Society for Medical Research SA Committee | Australian Society for Medical Research | Australia |
| Date | Role | Membership | Country |
|---|---|---|---|
| 2025 - ongoing | Member | International Women’s Forum Emerging Women Leadership Program | Australia |
| 2023 - 2025 | Member | AAMRI’s Deliberative Panel on Sex and Gender in Medical Research | Australia |
| 2017 - ongoing | Member | National Postdoctoral Association | United States |
| 2016 - ongoing | Member | Australian Society for Medical Research (ASMR) | Australia |
| 2015 - 2016 | Member | YWCA | - |
| 2006 - 2007 | Member | Australasian Society for HIV Medicine (ASHM) | Australia |
| Date | Topic | Presented at | Institution | Country |
|---|---|---|---|---|
| 2019 - 2019 | Invited Speaker: Spot the Bull Science | - | The Science Nation | Australia |
| 2019 - 2019 | Invited TEDx Oration: The Secret Life of a Scientist | TEDxFulbright, Adelaide 2019 | South Australian Health & Medical Research Institute | Australia |
Connect With Me
External Profiles
Available For Media Comment.